Synthesis, anti-angiogenic and DNA cleavage studies of novel N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)piperidine-4-carboxamide derivatives

Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med 1:27–31 Eckhardt S (2002) Recent progress in the development of anticancer agents. Cur Med Chem Anticancer Agents 3(2):419–439 Sreelatha S, Padma PR, Umadevi M (2009) Protective effect of corandrum sativum extracts on carbon tetrachloride-induced heptotoxity in rats. Food Chem Toxicol 47(4):702–708 Komiyama M, Sumaoka J (1998) Progress towards synthetic enzymes for phosphoester hydrolysis. Cur Opin Chem Biol 2(6):751–757 Hong J, Jiao Y, Yan J, He W, Guo Z, Zhu L, Zhang J (2010) DNA cleavage promoted by trigonal-bipyrimidal zinc(II) and copper(II) complexes formed by asymmetric tripodal tetradentate 2-[bis(2-aminoethyl)amino]ethanol. Inorg Chemica Acta 363(4):793–798 Marcaccino S, Pepino R, Pozo MC, Basurto S, Garia-valverde M, Torroba T (2004) One- pot synthesis of quinolin-2-(1H)-ones via tandem Ugi-Knoevenagel condensations. Tet Lett 45(21):3999–4001 Looper RE, Runnegar MTC, Williams RM (2005) Synthesis of the putative structure of 7-deoxycylindrospermopsin: C7-oxygenation is not required for the inhibition of protein synthesis. Angew Chemie Int Ed 44:3879–3881 Kobayashi J, Kanda F, Ishibashi M, Shigemori H, Manzacidins AC, Manzacidins AC (1991) Novel tetrahydropyrimidine alkaloids from the Okinawan marine sponge hymeniacidon sp. J Org Chem 56(14):4574–4576 Skinner GS, Wunz PR (1951) 2,5,5-Trialkyl-1,4,5,6-tetrahydropyrimidines. J Am Chem Soc 73(8):3814–3815 Chabner BA, Wilson W, Supko J (2001) Pharmocology and toxicity of antineoplastic drugs. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U (eds) William Hematology, 6th edn. McGraw-Hill, New York Hardman JG, Limbird LE, Molinof PB, Ruddon RW (2001) Gilman AG. In: Goodman G (ed) The pharmacological basics of therapeutics, 10th edn. McGraw-Hill, New York Brown DJ. Pyrimidines and their benzo derivatives. In: Katritzky AR, Rees CW, editors. Comprehensive heterocyclic chemistry The structure, reactions, synthesis and uses of heterocyclic compounds. Pergamon Press: Oxford; 1984. Vol. 3, pp-57 Ghoshal K, Jacob ST (1997) An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug. Biochem Pharmacol 53(11):1569–1575 Al-Safarjalani ON, Zhou XJ, Rais RH, Shi J, Schinazi RF, Naguib FNM, El Kouni MH (2005) 5-(Phenylthio)acyclouridine, a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens. Cancer Chemother Pharmacol 55(6):541–551 Lu X, Chen Y, Guo Y, Liu Z, Shi Y, Xu Y, Wang X, Zhang Z, Liu J (2007) The design and synthesis of N-1-alkylated-5-aminoarylalkylsubstituted-6-methyluracils as potential non-nucleoside HIV-1 RT inhibitors. Bioorg Med Chem 15(23):7399–7407 Wang X, Lou Q, Guo Y, Xu Y, Zhanga Z, Liu J (2006) The design and synthesis of 9-phenylcyclohepta[d]pyrimidine-2,4-dione derivatives as potent non-nucleoside inhibitors of HIV reverse transcriptase. Org Biomol Chem 4(17):3252–3258 McCarthy O, Musso-Buendia A, Kaiser M, Brun R, Ruiz-Perez LM, Johansson NG, Pacanowska DG, Gilbert IH (2009) Design, synthesis and evaluation of novel uracil acetamide derivatives as potential inhibitors of Plasmodium falciparum dUTP nucleotidohydrolase. Eur J Med Chem 44(2):678–688 Chang RSL, Chen T, O’Malley SS, Pettibone DJ, DiSalvo J, Francis B, Bock MG, Freidinger R, Nagarathnam D, Miao SW, Shen Q, Lagu B, Dhar TGM, Tyagarajan S, Marzabadi MR, Wong WC, Gluchowski C, Forray C (2000) In vitro studies on L-771,688 (SNAP 6383), a new potent and selective alpha1A-adrenoceptor antagonist. Eur J Pharmacol 409(3):301–312 Ikeda M, Maruyama K, Nobuhara Y, Yamada Y, Okabe S (1996) Synthesis and cytoprotective antiulcer activity of 2- or 4-(1H-pyrazol-1-yl)pyrimidine derivatives related to mepirizole and dulcerozine. Chem Pharm Bull 44(9):1700–1706 Falcao EPS, deMelo SJ, Srivastava RM, Catanho MTJA, Nascimento SC (2006) Synthesis and antiinflammatory activity of 4-amino-2-aryl-5-cyano-6-{3- and 4- (N-phthalimidophenyl)} pyrimidines. Eur J Med Chem 41(2):276–282 Goldberg HL, Finnerty RJ (1976) The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am J Psych 136(9):1184–1187 Kohlhoff SA, Sharma RI (2007) Expert Opin Invest Drugs 16(9):1441–1448 Locher HH, Schlunegger H, Hartman PG, Anghern P, Then RL (1996) Antibacterial activities of epiroprim, a new dihydrofolate reductase inhibitor, alone and in combination with dapsone. Antimicrob Agents Chemother 40:1376–1381 Morgan A, Cofer C, Stevens DL (2009) Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections. Fut Microbiol 4(2):131–144 Mai A, Rotili D, Massa S, Brosch G, Simonetti G, Passariello C, Palamar AT (2007) Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans. Bioorg Med Chem Lett 17(5):1221–1225 Aleem G, Sonali K, Michael AI, Jessica ET, Satyendra SS (2010) Synthesis and biological activity of N4-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agents. Bioorg Med Chem 18(10):3575–3587 Wang S, Meades C, Wood G, Osnowski A, Anderson S, Yuill R, Thomas M, Mezna M, Jackson W, Midgley C, Griffiths G, Fleming I, Green S, McNae I, Wu S, McInnes C, Zheleva D, Walkinshaw MD, Fischer PM (2004) 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, sar analysis, X-ray crystallography, and biological activity. J Med Chem 47(7):1662–1675 Brugel TA, Maier JA, Clark MP, Sabat M, Golebiowski A, Bookland RG, Laufersweiler MJ, Laughlin SK, VanRens JC, De B, Hsieh LC, Mekel MJ, Janusz MJ (2006) Development of N-2,4-pyrimidine-N-phenyl-N’-phenyl ureas as inhibitors of tumor necrosis factor alpha (TNF-alpha) synthesis Part 1. Bioorg Med Chem Lett. 16(13):3510–3513 Zimmermann J, Buchdunger E, Mett H, Meyer T, Lydon NB (1997) Potent and selective inhibitors of the abl-kinase: phenylamino-pyrimidine (PAP) derivatives. Bioorg Med Chem Lett 7(2):187–192 Bailey JP, Giles MB, Pass M. 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer. WO 2006005914 A1, 2006 Bilodeau MT, Chua PC, Cosford NDP, Hoffman JM, Nagasawa J. WO 2005100344 A1, 2005 Srinivas ASSV, Tadiparthi R, Sharma GVR, Thirunavukkarasu S, Bhakiaraj DP, Kachhadia V, Narsimhan K, Thara SN, Rajagopal S, Reddy G, Narayanan S, Parameswaran V, Janarthanam V. US 20070167413 A1, 2007 Demetri GD, von Mehren M, Blanke CD (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New Eng J Med 347(7):472–480 Peggs K, Mackinnon S (2003) Imatinib mesylate-the new gold standard for treatment of chronic myeloid leukemia. New Eng J Med 348(11):1048–1050 Vinaya K, Kavitha CV, Chandrappa S, Prasanna DS, Sateesh CR, Rangappa KS (2012) Synthesis and Antileukemic Activity of Novel 2-(4-(2,4-dimethoxybenzoyl)phenoxy)-1-(4-(3-(piperidin-4-yl)propyl)piperidin-1-yl) ethanone Derivatives. Chem Biol Drug Des 79(3):360–367 Vinaya K, Kavitha CV, Prasanna DS, Chandrappa S, Raghavan SC, Rangappa KS (2011) Synthesis and antileukemic activity of novel 4-(3-(piperidin-4-yl)propyl) piperidine derivatives. Chem Biol Drug Des 78(4):622–630 Vinaya K, Raja N, Ananda Kumar CS, Benaka Prasad SB, Chandrappa S, Ranganatha SR, Krishna V, Rangappa KS (2009) Evaluation of in vivo wound-healing potential of 2-[4-(2,4-dimethoxy-benzoyl)-phenoxy]-1-[4-(3-piperidin-4-yl-propyl)-piperidin-1-yl]-ethanone derivatives. Eur J Med Chem 44(8):3158–3165 Auerbach R, Kubai L, Knighton D, Folkman J (1974) A simple procedure for the long- term cultivation of chicken embryos. Dev Biol 41(2):391–394 Michael RG, Sambrook J (2012) Molecular cloning, a laboratory manual, 4th edn. Cold Spring Harbor Laboratory Press, New York Chang S, Yin SL, Wang J, Jing YK, Dong JH (2009) Design and synthesis of novel 2-phenylaminopyrimidine (PAP) derivatives and their antiproliferative effects in human chronic myeloid leukemia cells. Molecules 14(10):4166–4179 Weitensteiner SB, Liebl J, Krystof V, Havlicek L, Gucky T, Strnad M, Furst R, Vollmar AM, Zahler S (2013) Trisubstituted pyrazolopyrimidines as novel angiogenesis inhibitors. PLoS ONE 8(1):e54607 Miyazaki Y, Tang J, Maeda Y, Nakano M, Wang L, Nolte RT, Sato H, Sugai M, Okamoto Y, Truesdale AT, Hassler DF, Nartey EN, Patrick DR, Hoc ML, Ozawa K (2007) Orally active 4-amino-5-diarylurea-furo[2,3-d]pyrimidine derivatives as anti-angiogenic agent inhibiting VEGFR2 and Tie-2. Bioorg Med Chem Lett 17(6):1773–1778 Xiao-Yun W, Wen-Hua C, Shu-Guang W, Yuan-Xin T, Jia-Jie Z (2012) Pyrrolo[3,2-d]pyrimidine derivatives as type II kinase insert domain receptor (KDR) inhibitors: CoMFA and CoMSIA studies. Int J Mol Sci 13(2):2387–2404 Donnini S, Mont M, Castagnini C, Solito R, Botta M, Schenone S, Giachetti A, Ziche M (2006) Pyrazolo–pyrimidine-derived c-Src inhibitor reduces angiogenesis and survival of squamous carcinoma cells by suppressing vascular endothelial growth factor production and signaling. Int J Cancer 120(5):995–1004 Keri RS, Hosamani KM, Shingalapur RV, Hugar MH (2010) Analgesic, anti-pyretic and DNA cleavage studies of novel pyrimidine derivatives of coumarin moiety. Eur J Med Chem 45(6):2597–2605 Shamsuzzaman DAM, Yaseen Z, Alam K, Hussain A, Gatoo MA (2013) Steroidal pyrimidines: synthesis, characterization, molecular docking studies with DNA and in vitro cytotoxicity. J Mol Struct 1045(6):62–71